Karleen Habin

1.6k total citations
27 papers, 520 citations indexed

About

Karleen Habin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Karleen Habin has authored 27 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Genetics. Recurrent topics in Karleen Habin's work include BRCA gene mutations in cancer (7 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Karleen Habin is often cited by papers focused on BRCA gene mutations in cancer (7 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Karleen Habin collaborates with scholars based in United States, Netherlands and France. Karleen Habin's co-authors include Eric P. Winer, Leif W. Ellisen, Beth Overmoyer, Nadine Tung, SJ Isakoff, Vincent L. Giranda, Meghan Underhill‐Blazey, Paul E. Goss, R. S. Gelman and Sonika Dahiya and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Karleen Habin

25 papers receiving 498 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karleen Habin United States 12 311 167 156 132 122 27 520
Meghna S. Trivedi United States 16 428 1.4× 95 0.6× 135 0.9× 136 1.0× 154 1.3× 60 664
Amy Comander United States 10 211 0.7× 102 0.6× 177 1.1× 102 0.8× 102 0.8× 30 417
Stanley Hooker United States 16 129 0.4× 187 1.1× 118 0.8× 310 2.3× 224 1.8× 26 735
Beom Seok Ko South Korea 16 358 1.2× 100 0.6× 412 2.6× 74 0.6× 121 1.0× 88 825
Luisel Ricks‐Santi United States 14 187 0.6× 181 1.1× 150 1.0× 126 1.0× 108 0.9× 42 526
Marie-Louise Fjällskog Sweden 19 501 1.6× 176 1.1× 179 1.1× 209 1.6× 97 0.8× 40 1.0k
Douglas F. Easton United Kingdom 5 325 1.0× 159 1.0× 145 0.9× 421 3.2× 30 0.2× 8 671
Jennifer Permuth‐Wey United States 12 352 1.1× 436 2.6× 453 2.9× 68 0.5× 89 0.7× 16 939
Jeanna McCuaig Canada 14 158 0.5× 103 0.6× 139 0.9× 320 2.4× 36 0.3× 39 490
Melanie Seal Canada 9 202 0.6× 132 0.8× 135 0.9× 30 0.2× 96 0.8× 25 447

Countries citing papers authored by Karleen Habin

Since Specialization
Citations

This map shows the geographic impact of Karleen Habin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karleen Habin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karleen Habin more than expected).

Fields of papers citing papers by Karleen Habin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karleen Habin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karleen Habin. The network helps show where Karleen Habin may publish in the future.

Co-authorship network of co-authors of Karleen Habin

This figure shows the co-authorship network connecting the top 25 collaborators of Karleen Habin. A scholar is included among the top collaborators of Karleen Habin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karleen Habin. Karleen Habin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Jing, Tanya E. Keenan, Beth Overmoyer, et al.. (2021). Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research and Treatment. 189(3). 641–651. 15 indexed citations
2.
Abraham, Elizabeth, et al.. (2020). Cutaneous Metastases: A Case Study on Clinical Care for Patients. Clinical journal of oncology nursing. 24(3). 320–323.
3.
Spring, Laura M., Steven J. Isakoff, Beverly Moy, et al.. (2020). Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER).. Journal of Clinical Oncology. 38(15_suppl). 531–531. 3 indexed citations
4.
Abraham, Elizabeth, Kathryn Post, Laura M. Spring, et al.. (2018). Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. Clinical journal of oncology nursing. 22(3). E71–E77. 1 indexed citations
5.
Vidula, Neelima, Dejan Juric, Andrzej Niemierko, et al.. (2018). Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology. 36(15_suppl). 1020–1020. 34 indexed citations
6.
Isakoff, Steven J., Gary S. Rogers, Samuel L. Hill, et al.. (2017). An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using verteporfin for the treatment of cutaneous breast cancer metastases.. Journal of Clinical Oncology. 35(15_suppl). TPS1121–TPS1121. 11 indexed citations
7.
Isakoff, Steven J., Sara M. Tolaney, Nadine Tung, et al.. (2017). A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS1126–TPS1126. 11 indexed citations
8.
Underhill‐Blazey, Meghan, et al.. (2016). Disparities in Cancer Genetic Risk Assessment and Testing. Oncology nursing forum. 43(4). 519–523. 28 indexed citations
9.
Underhill‐Blazey, Meghan, Karleen Habin, & Kristen M. Shannon. (2016). Perceptions of Cancer Risk, Cause, and Needs in Participants from Low Socioeconomic Background at Risk for Hereditary Cancer. Behavioral Medicine. 43(4). 259–267. 5 indexed citations
10.
Flanagan, Jane, et al.. (2016). The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor–Positive Breast Cancer. Oncology nursing forum. 43(4). E143–E152. 6 indexed citations
11.
Habin, Karleen, et al.. (2014). Cancer Genetics and Genomics: Essentials for Oncology Nurses. Clinical journal of oncology nursing. 18(3). 355–359. 5 indexed citations
12.
Flanagan, Jane, et al.. (2011). Women's Experiences With Antiestrogen Therapy to Treat Breast Cancer. Oncology nursing forum. 39(1). 70–77. 10 indexed citations
13.
Isakoff, SJ, Beth Overmoyer, Nadine Tung, et al.. (2010). A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 1019–1019. 122 indexed citations
14.
Habin, Karleen, et al.. (2010). "I Feel Like I Am 100 Years Old!" Managing Arthralgias From Aromatase Inhibitors. Clinical journal of oncology nursing. 14(3). 379–382. 20 indexed citations
15.
Joffe, Hadine, Ann Partridge, Anita Giobbie‐Hurder, et al.. (2010). Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. Menopause The Journal of The North American Menopause Society. 17(5). 908–916. 32 indexed citations
16.
Bauer‐Wu, Susan, Katherine A. Yeager, Rebecca Norris, et al.. (2009). Communication and planning at the end-of-life: A survey of women with advanced stage breast cancer. Journal of Communications In Healthcare. 2(4). 371–386. 9 indexed citations
17.
Wittner, Ben S., Dennis C. Sgroi, Paula D. Ryan, et al.. (2008). Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort. Clinical Cancer Research. 14(10). 2988–2993. 115 indexed citations
18.
Paskett, Electra D., James E. Herndon, Jeannette M. Day, et al.. (2008). Applying a conceptual model for examining health‐related quality of life in long‐term breast cancer survivors: CALGB study 79804. Psycho-Oncology. 17(11). 1108–1120. 30 indexed citations
19.
Habin, Karleen, et al.. (2007). Aromatase Inhibitors and Musculoskeletal Pain in Patients With Breast Cancer. Clinical journal of oncology nursing. 11(3). 433–439. 14 indexed citations
20.
Kozak, Kevin R., Karen P. Doppke, Michele A. Gadd, et al.. (2005). Feasibility of Simple 3D Conformal External-Beam Accelerated Partial Breast Irradiation (APBI): Initial Dosimetric Experience. International Journal of Radiation Oncology*Biology*Physics. 63. S10–S10. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meghna S. Trivedi Breakdown of academic impact, for papers by Amy Comander Breakdown of academic impact, for papers by Stanley Hooker Breakdown of academic impact, for papers by Beom Seok Ko Breakdown of academic impact, for papers by Luisel Ricks‐Santi Breakdown of academic impact, for papers by Marie-Louise Fjällskog Breakdown of academic impact, for papers by Douglas F. Easton Breakdown of academic impact, for papers by Jennifer Permuth‐Wey Breakdown of academic impact, for papers by Jeanna McCuaig Breakdown of academic impact, for papers by Melanie Seal
Rankless by CCL
2026